Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C

Importance of patient's motivation and physician's treatment experience

Daisuke Tanioka, Yoshiaki Iwasaki, Yasuyuki Araki, Toshiya Osawa, Hiroshi Ikeda, Masaharu Ando, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori, Kazuhide Yamamoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims: Adherence to combination therapy with interferon (IFN) or pegylated IFN plus ribavirin for chronic hepatitis C patients is important for a better virological response. However, the impact of the patient's treatment experience and treatment centre on adherence to combination therapy has not been fully analysed. In this prospective study, we analysed the factors that might have an effect on adherence to therapy in patients who had initial or retreatment IFN therapy. Patients and methods: We consecutively enrolled 363 patients with chronic hepatitis C; 221 were IFN naïve and 142 were undergoing retreatment. The mean ages of the naïve and retreatment groups were 54.8 and 55.7 years respectively. IFN α-2b was administered daily for 2 weeks, followed by three times per week for 22 weeks, while ribavirin was administered daily. We evaluated the tolerability and response to combination therapy and analysed its relevant factors. Results: Of the 363 patients, 189 (52%) achieved 80% adherence. The multivariate logistic regression analysis revealed that retreatment, centre with more patients treated, patient age (

Original languageEnglish
Pages (from-to)721-729
Number of pages9
JournalLiver International
Volume29
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Physicians
Retreatment
Therapeutics
Logistic Models
Regression Analysis
Prospective Studies

Keywords

  • Adherence
  • Retreatment
  • Treatment centre
  • Treatment experience

ASJC Scopus subject areas

  • Hepatology

Cite this

Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C : Importance of patient's motivation and physician's treatment experience. / Tanioka, Daisuke; Iwasaki, Yoshiaki; Araki, Yasuyuki; Osawa, Toshiya; Ikeda, Hiroshi; Ando, Masaharu; Kobashi, Haruhiko; Sakaguchi, Kohsaku; Shiratori, Yasushi; Yamamoto, Kazuhide.

In: Liver International, Vol. 29, No. 5, 2009, p. 721-729.

Research output: Contribution to journalArticle

Tanioka, Daisuke ; Iwasaki, Yoshiaki ; Araki, Yasuyuki ; Osawa, Toshiya ; Ikeda, Hiroshi ; Ando, Masaharu ; Kobashi, Haruhiko ; Sakaguchi, Kohsaku ; Shiratori, Yasushi ; Yamamoto, Kazuhide. / Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C : Importance of patient's motivation and physician's treatment experience. In: Liver International. 2009 ; Vol. 29, No. 5. pp. 721-729.
@article{01c3bd001a9b4b38acaf78838647bed9,
title = "Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: Importance of patient's motivation and physician's treatment experience",
abstract = "Background/Aims: Adherence to combination therapy with interferon (IFN) or pegylated IFN plus ribavirin for chronic hepatitis C patients is important for a better virological response. However, the impact of the patient's treatment experience and treatment centre on adherence to combination therapy has not been fully analysed. In this prospective study, we analysed the factors that might have an effect on adherence to therapy in patients who had initial or retreatment IFN therapy. Patients and methods: We consecutively enrolled 363 patients with chronic hepatitis C; 221 were IFN na{\"i}ve and 142 were undergoing retreatment. The mean ages of the na{\"i}ve and retreatment groups were 54.8 and 55.7 years respectively. IFN α-2b was administered daily for 2 weeks, followed by three times per week for 22 weeks, while ribavirin was administered daily. We evaluated the tolerability and response to combination therapy and analysed its relevant factors. Results: Of the 363 patients, 189 (52{\%}) achieved 80{\%} adherence. The multivariate logistic regression analysis revealed that retreatment, centre with more patients treated, patient age (",
keywords = "Adherence, Retreatment, Treatment centre, Treatment experience",
author = "Daisuke Tanioka and Yoshiaki Iwasaki and Yasuyuki Araki and Toshiya Osawa and Hiroshi Ikeda and Masaharu Ando and Haruhiko Kobashi and Kohsaku Sakaguchi and Yasushi Shiratori and Kazuhide Yamamoto",
year = "2009",
doi = "10.1111/j.1478-3231.2008.01964.x",
language = "English",
volume = "29",
pages = "721--729",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C

T2 - Importance of patient's motivation and physician's treatment experience

AU - Tanioka, Daisuke

AU - Iwasaki, Yoshiaki

AU - Araki, Yasuyuki

AU - Osawa, Toshiya

AU - Ikeda, Hiroshi

AU - Ando, Masaharu

AU - Kobashi, Haruhiko

AU - Sakaguchi, Kohsaku

AU - Shiratori, Yasushi

AU - Yamamoto, Kazuhide

PY - 2009

Y1 - 2009

N2 - Background/Aims: Adherence to combination therapy with interferon (IFN) or pegylated IFN plus ribavirin for chronic hepatitis C patients is important for a better virological response. However, the impact of the patient's treatment experience and treatment centre on adherence to combination therapy has not been fully analysed. In this prospective study, we analysed the factors that might have an effect on adherence to therapy in patients who had initial or retreatment IFN therapy. Patients and methods: We consecutively enrolled 363 patients with chronic hepatitis C; 221 were IFN naïve and 142 were undergoing retreatment. The mean ages of the naïve and retreatment groups were 54.8 and 55.7 years respectively. IFN α-2b was administered daily for 2 weeks, followed by three times per week for 22 weeks, while ribavirin was administered daily. We evaluated the tolerability and response to combination therapy and analysed its relevant factors. Results: Of the 363 patients, 189 (52%) achieved 80% adherence. The multivariate logistic regression analysis revealed that retreatment, centre with more patients treated, patient age (

AB - Background/Aims: Adherence to combination therapy with interferon (IFN) or pegylated IFN plus ribavirin for chronic hepatitis C patients is important for a better virological response. However, the impact of the patient's treatment experience and treatment centre on adherence to combination therapy has not been fully analysed. In this prospective study, we analysed the factors that might have an effect on adherence to therapy in patients who had initial or retreatment IFN therapy. Patients and methods: We consecutively enrolled 363 patients with chronic hepatitis C; 221 were IFN naïve and 142 were undergoing retreatment. The mean ages of the naïve and retreatment groups were 54.8 and 55.7 years respectively. IFN α-2b was administered daily for 2 weeks, followed by three times per week for 22 weeks, while ribavirin was administered daily. We evaluated the tolerability and response to combination therapy and analysed its relevant factors. Results: Of the 363 patients, 189 (52%) achieved 80% adherence. The multivariate logistic regression analysis revealed that retreatment, centre with more patients treated, patient age (

KW - Adherence

KW - Retreatment

KW - Treatment centre

KW - Treatment experience

UR - http://www.scopus.com/inward/record.url?scp=64749093949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749093949&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2008.01964.x

DO - 10.1111/j.1478-3231.2008.01964.x

M3 - Article

VL - 29

SP - 721

EP - 729

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -